H. Calvert

Cancer Drug Development in Europe: A Selection of New Agents Under Development at the European Drug Development Network

D. Lacombe, P. Therasse, J. Verweij, 2003, Cancer Investigation.

Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies

M. Gore, R. Paridaens, J. Wanders, 2002, Investigational New Drugs.

AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)

L. Duchateau, T. Čufer, C. Twelves, 2000 .